Argos Therapeutics (ARGS) 6.30 $ARGS Buy 5 Attractive

New Post Public Reply Private Reply Replies (0) Message Board

Jul 12, 2016 at 2:05 AM

Argos Therapeutics (ARGS) 6.30 $ARGS

Buy 5 Attractive Biotechs at Bargain Prices
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 11:07AM CDT
Amid the recent wave of consolidations, it makes sense to zero in on some low-priced biotechs below $10 carrying a Zacks Rank #1 (Strong Buy) or Zacks Rank #2 (Buy).
MACK: 5.54 (-0.08), ARGS: 6.30 (+0.06), IDRA: 1.68 (unch), AVXL: 7.73 (+0.15), AVEO: 0.95 (unch)

5 Top Biotech Performers of 2016
Afrasiab Mian - Zacks Investment Research - Fri Jul 01, 4:19PM CDT
2016 has been a busy year for the Biotech industry. Let's take a look 5 of the strongest year-to-date (YTD) performers.
XBIT: 19.35 (+3.57), ARGS: 6.30 (+0.06), OPXA: 4.39 (+0.13), ANIP: 55.38 (-1.13), RPRX: 1.72 (-0.01)

Apple and Hanesbrands fall, LinkedIn and Symantec climb
AP - Mon Jun 13, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
ARGS: 6.30 (+0.06), LNKD: 190.27 (-0.17), EBIO: 2.52 (+0.04), DUK: 86.01 (unch), HBI: 26.26 (-0.01), AAPL: 96.98 (+0.30), SYMC: 20.80 (+0.10)

Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Positive outcome triggers the second tranche of the Company's previously announced financing agreement
ARGS: 6.30 (+0.06)

Argos Therapeutics to Participate in Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 08, 3:05PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the Jefferies 2016 Healthcare Conference to be held June 7-10 at the Grand Hyatt in New York City.
ARGS: 6.30 (+0.06)

Earnings Estimates Moving Higher for Argos Therapeutics (ARGS): Time to Buy?
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:37AM CDT
Positive earnings estimate revisions, coupled with impressive Zacks Rank has made Argos Therapeutics (ARGS) an interesting choice for the investors.
ARGS: 6.30 (+0.06)

Argos Therapeutics Reports First Quarter 2016 Financial Results and Operational Highlights
GlobeNewswire - Thu May 12, 3:05PM CDT
- Entered into Equity Financing for Up to $60 million -
ARGS: 6.30 (+0.06)

Argos Therapeutics to Host First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016
GlobeNewswire - Thu May 05, 7:00AM CDT
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"

, an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on the Arcelis(R) technology platform, today announced that the Company's first quarter 2016 financial results will be released after the market close on Thursday, May 12, 2016. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.
ARGS: 6.30 (+0.06)

3 Buy-Ranked Healthcare Stocks Building Momentum Now
Zacks Premium Research - Zacks Investment Research - Mon Apr 25, 3:57PM CDT
These healthcare stocks have posted double digit share price gains over the last month, but we're talking about another kind of momentum that makes these corporations worth betting on.
ARGS: 6.30 (+0.06), INVA: 11.77 (+0.13), VTAE: 10.61 (-0.12), GSK: 43.52 (+0.14)

Insider Bets Paying Off At ARGS As New 52-Week High Reached
MarketNewsVideo.com - Wed Apr 13, 12:13PM CDT
In trading on Wednesday, shares of Argos Therapeutics Inc. touched a new 52-week high of $9.41/share.
ARGS: 6.30 (+0.06)

Surging Earnings Estimates Signal Good News for Argos Therapeutics (ARGS)
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 7:44AM CDT
Positive earnings estimate revisions, coupled with impressive Zacks Rank has made Argos Therapeutics (ARGS) an interesting choice for the investors.
ARGS: 6.30 (+0.06)

Can The Uptrend Continue for Argos Therapeutics (ARGS)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 8:28AM CDT
Investors certainly have to be happy with Argos Therapeutics, Inc. (ARGS) and its short term performance
ARGS: 6.30 (+0.06)

Argos Therapeutics to Participate in 15th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 07, 3:05PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the 15 Annual Needham Healthcare Conference to be held April 12-13 at the Westin New York Grand Central in New York City.
ARGS: 6.30 (+0.06)

The Last Time This Company Made A FDA Submission It Ran 2,100%-- Here's Why You Should Be Looking At It Right Now
ACCESSWIRE - Wed Mar 30, 6:00AM CDT
WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or "WBT"

, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight that the maximum gains are made by investors who seek out promising pharma companies before their filing of FDA approval.
AGEN: 4.71 (-0.08), ARGS: 6.30 (+0.06)

CORRECTION -- Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
GlobeNewswire - Tue Mar 29, 5:12PM CDT
In the release issued earlier today by Argos Therapeutics (Nasdaq:ARGS), please note that the "Selected Third Quarter 2015 Financial Results" header should be "Selected Fourth Quarter and Full-Year 2015 Financial Results." All other information in the press release remains the same.
ARGS: 6.30 (+0.06)

Argos Therapeutics reports 4Q loss
Automated Insights - Tue Mar 29, 3:59PM CDT
DURHAM, N.C. (AP) _ Argos Therapeutics Inc. (ARGS) on Tuesday reported a loss of $17.6 million in its fourth quarter.
ARGS: 6.30 (+0.06)

Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
GlobeNewswire - Tue Mar 29, 3:30PM CDT
- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 in July 2015 -
ARGS: 6.30 (+0.06)

Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy
GlobeNewswire - Wed Mar 23, 7:00AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"

, an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis(R) technology platform, today announced the initiation of an investigator-sponsored Phase 2 clinical trial of AGS-003 in combination with standard platinum-doublet chemotherapy with or without radiation in patients with newly diagnosed Stage 3 non-small cell lung cancer (NSCLC).
ARGS: 6.30 (+0.06)

Argos Therapeutics to Host Fourth Quarter and Full-Year 2015 Financial Results Conference Call on Tuesday, March 29, 2016
GlobeNewswire - Tue Mar 22, 3:05PM CDT
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"

, an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis(R) technology platform, today announced that the Company's fourth quarter and full-year 2015 financial results will be released after the market closes on Tuesday, March 29, 2016. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.
ARGS: 6.30 (+0.06)

Argos Therapeutics to Participate in 6th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
GlobeNewswire - Tue Mar 22, 7:00AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"

, an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the 6 Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference to be held on March 31, 2016 at the Apella Event Space Alexandria Center in New York City.
ARGS: 6.30 (+0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

California Contractors Honored for Safety Commitment

Commitment to Safety in the Construction Industry When it comes to construction, safety isn’t an afterthought—it’s woven into the very fabric of every project. The 39th Annual Construction Safety Excellence Awards by the Associated General Contractors of California (AGC of California) pits a spotlight on those embodying this ethos. Industry Leaders in Safety Held on...

Grid Hurdles Stalling Industrial Heat's Future Growth

The Grid's the New Ball and Chain Now that we're done fiddling with tech, let's talk grid. The industrial players itching to switch to electric heat have found a new villain: the grid. You'd think with resistance heating, electric boilers, electric arc furnaces, and the whole shebang ready to roll, it’d be a smooth ride. But nope, the bottleneck's the bloodstream...

Rising Rates and War in Iran Hit Investor Nerves

An Unsettling Mix for Real Estate Investors The latest RCN Capital Investor Sentiment Survey reveals a shaky real estate landscape, plagued by a mix of geopolitical conflict and central bank policy changes. You know you're in trouble when investor sentiment just crawls back from an all-time low, bouncing barely from an index score of 84 to 89. It's the kind of timid...

Strategic Moves in Biotech: The EQT-Qiagen Deal EQT Private Equity's latest maneuver has seasoned investors raising an eyebrow. They've just put an all-cash public takeover offer on the table for Qiagen, and no, this isn't your run-of-the-mill acquisition—it's a play steeped in strategy and capital dynamics. EQT's Portfolio Puzzle: Where Does Qiagen Fit? Let's break it...

Phoenix Reveals Cost-Saving Hacks for Transfer Students

Making College Cost Manageable Okay, let's get real about college costs. Tuition fees got folks holding their breath tighter than a bull in a bear market. University of Phoenix ain't turning a blind eye—during National Transfer Student Week, they're shouting from the rooftops about pocket-friendly ways to snag that degree without selling your soul or flipping another...

Endeavour and Trevi Turn Data Centers Into Water Sources

Turning Data Centers Into Wells If you'd told me data centers could double as water sources, I'd have laughed you off. But this week brings us a game-changing partnership between Endeavour and Trevi Systems. They're using the waste heat from data centers to create clean water, tackling water scarcity in the process. Imagine this: for every megawatt of computing power, up...

CMCC Global Pioneers Tokenized Funds in El Salvador

A Bold Move into Tokenization Tokenization: it's the buzzword that's got folks scratching their heads and bankers keeping an extra bottle of aspirin in their desk drawers. CMCC Global is diving headlong into this brave new world, rolling out two tokenized fund-of-funds right under El Salvador's fresh digital asset rules. Now that's gutsy. The Partners in Innovation...

Revving Up for Cars.com's Q3 2026 Results Announcement

The Road Ahead for Cars in 2026 Wander into the fast lane, and you’ll find Cars.com, a heavyweight in the realm of car sales, priming itself to roll out its financial report for the third quarter of 2026. Scheduled for November 5, it’s bound to catch the eye of investors itching to gauge where this auto marketplace stands amidst changing tides in the industry. A Look...

Arclin's Bold Bet: Expanding Nomex Capacity in Spain

Arclin's Strategic Move for Nomex® Expansion Looks like Arclin’s not messing around. They're throwing some serious cash down in Asturias, Spain, to ramp up production of Nomex®—a material hotter than a blacktop in July with demand surging across aerospace, electric vehicles, and defense sectors. "When we bought the Nomex® business, we committed to investing in its...

MLS Org's Sue Compass to Safeguard Fair Listing Access

Real Estate Clash: MLS vs. Compass Imagine flipping on the TV to see a legal showdown brewing in the real estate world — you've got six heavy-hitter MLSs facing off against Compass, Inc. Yeah, we're talking a legal slugfest here, folks, as these MLSs rally to keep the playing field level for over 120,000 agents across the country. They're not messing around, bringing a...